CMB International Securities  Equity Research Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Healthcare Sector
Jill Wu CFA
Sam HU PhD
Mkt Cap (RMB mn)
Avg 3mths to (RMB mn)
52W HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
A-share public shareholders
H-share public shareholders
Source Bloomberg
Source Bloomberg
12-mth price performance
Source Bloomberg
Auditor Deloitte Touche Tohmatsu
COVID-19 pandemic  17 Aug 2020
Strong core business growth  26
Strengthening leading position in
global CROCDMO industry  13 Dec
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP
RMB13198)
UpDownside
 Strong growth acceleration in 3Q20 WuXi AppTec reported third-quarter
revenue of RMB458bn up 354% YoY Non-IFRS net profit was up 443% YoY
to RMB958mn Attributable net profit decreased 81% YoY to RMB651mn mainly
due to foreign exchange loss Third-quarter has achieved significant growth
services US - based laboratory services and Clinical research  other CRO
services realized 389% 549% -135% 168% YoY change in revenue
 CDMO and China-based lab service continue to be major growth driver
CDMO service and China-base lab service recorded a YoY growth of 549%
389% in 3Q20 and 365% 309% in 9M20 Such strong performance offset
the challenges faced by the US-based laboratory services due to the COVID-
19 pandemic Thanks to follow-the-molecule strategy the Company added
440 new molecules into its CDMO pipeline YTD and total CDMO pipeline has
projects 42 Phase III projects During the same period WuXi AppTec has
submitted IND filings for 18 new chemical entities (NCE) for its customers and
obtained 20 CTAs in China Cumulatively WuXi AppTec has submitted 103
NCE IND filings with the NMPA and obtained 77 CTAs including 1 project in
Phase III clinical trial 9 projects in Phase II clinical trials and 56 projects in
Phase I clinical trials
 Globalization strategy to enable innovation worldwide YTD WuXi
AppTec added over 900 new customers and provided services to a wide range
worldwide In 9M20 overseas customers contributed 764% of total revenue
while China customers accounted for 236% of revenue representing a YoY
growth of 253% and 344% respectively Driven by the long-tail strategy
Long-tail  China customers 672% of total revenue up 284% YoY in 9M20
 We lifted SOTP-based TP from RMB13198 to RMB13905 to reflect
strong long-term growth outlook for WuXi AppTec We forecast WuXi
AppTecs adjusted Non-IFRS attributable net profit to grow by 35%33%32%
YoY in FY20E21E22E respectively and attributable net profit to increase
85%22%32% YoY in FY20E21E22E Moreover WuXi AppTec maintained
a diversified investment portfolio which will bring significant investment gains
over the long term
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
YoY growth (%)
YoY growth (%)
Change (%)
Consensus EPS (RMB)
Net gearing (%)
Source Company data Wind CMBIS estimates
WuXi AppTec (603259 CH)
Accelerated growth in 3Q20 driven by strong
performance in CDMO and China-base lab service
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 CMBIS earnings revisions
Source CMBIS estimates
Figure 2 CMBIS vs consensus
Source Bloomberg CMBIS estimates
Figure 2 SOTP valuation
Attributable Non-IFRS net profit (RMB mn)
PE multiple of core business
Valuation of CROCDMO business (RMB mn)
Fair value of other non-current financial assets (RMB mn)
PB multiple of investment business
Valuation of investment business (RMB mn)
SOTP valuation (RMB mn)
 of shares
Target price (RMB per share)
Source CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E
China-based lab services
8484 11029 14338  Depreciation and amortization
CMOCDMO services
8970  Change in working capital
US-based laboratory services
2428  Investment loss (gain)
Clinical research  other
2122  Other operating activities
43  Net cash from operating
Acquisition of subsidiaries
(61)  Other investing activities
Selling  distribution expenses
(893)  Net cash from investing
Administrative expenses
RD expenses
(928) (1200)  Net proceeds from shares issued
5836  Net borrowings
Acquisition of non-controlling
Finance costs net
0  Dividends and interests paid
100  Other financing activities
Net gain from FV changes
461  Net cash from financing
Pre-tax profit
(984)  Net change in cash
(45)  Cash at the beginning of the year
5529  Cash at the end of the year
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec
FY18A FY19A FY20E FY21E FY22E
Non-current assets
6732  China-based lab services
705  CMOCDMO services
9223 11284  US-based laboratory services
Clinical research and other
Other non-current assets
5138  Others
11807 12663 21661 22764 25492  Profit  loss ratios (%)
2918  EBITDA margin
Trade and bills receivables
5045  Pre-tax margin
Prepayments deposits
and other receivables
123  Net margin
2609  Effective tax rate
7267  Balance sheet ratios
104  Current ratio (x)
Trade and other payables
2724  Trade receivables turnover days
Other current liabilities
4438  Trade payables turnover days
Net debt to total equity ratio (%) Net cash
1 Net cash Net cash Net cash
Non-current liabilities
762  Returns (%)
Other non-current liabilities
2933  ROE
203  Per share
Shareholders equity
BVPS (RMB)
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in
the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or
its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
CMBIS is not a registered broker-dealer in the United States  As a result CMBIS is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or
qualified as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA
Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report
is intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing
to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as
defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced
by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers
Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined
in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the
extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report